Financial Performance - The company's revenue for Q3 2025 was ¥144,907,398.09, representing a decrease of 12.57% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥21,783,561.40, an increase in loss of 58.05% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥23,058,299.19, which is 58.81% worse than the previous year[5]. - The company's basic earnings per share for Q3 2025 was -¥0.0628, a deterioration of 57.71% compared to the same period last year[5]. - The company's operating income for the first nine months of 2025 was ¥429,263,703.57, down 7.12% from ¥462,193,617.06 in the same period last year[10]. - Total revenue for the current period is RMB 429.26 million, a decrease of 7.1% from RMB 462.19 million in the previous period[22]. - The company reported a net profit of -107,028,427.53 yuan, compared to -172,457,181.76 yuan in the previous period, indicating an improvement of approximately 38%[23]. - Operating profit was -105,012,150.37 yuan, an improvement from -170,517,779.03 yuan year-over-year[23]. - The total comprehensive income attributable to the parent company was -97,298,376.26 yuan, compared to -158,577,188.07 yuan in the previous period, showing an improvement of about 39%[24]. - Basic earnings per share were -0.2789, an improvement from -0.4498 in the previous period[24]. Cash Flow - Cash flow from operating activities showed a significant increase of 198.95%, totaling ¥47,642,907.07 year-to-date[5]. - Cash flow from operating activities turned positive at ¥47,642,907.07, a substantial increase of 198.95% compared to the previous year, driven by organizational restructuring[11]. - The net cash flow from operating activities was 47,642,907.07 yuan, a significant recovery from -48,147,116.27 yuan in the previous period[26]. - Cash flow from investing activities improved to ¥23,094,484.86, a 120.91% increase, mainly due to the receipt of funds from the sale of a 90% stake in a pharmaceutical company[11]. - Cash flow from financing activities decreased to -¥125,735,648.52, a decline of 180.89%, resulting from reduced borrowings and increased debt repayments[11]. Assets and Liabilities - The total assets at the end of Q3 2025 were ¥2,580,324,640.17, down 7.63% from the end of the previous year[5]. - The company's cash and cash equivalents decreased to RMB 259.09 million from RMB 307.18 million, a decline of 15.6%[18]. - Total assets decreased to RMB 2.58 billion from RMB 2.79 billion, a decline of 7.6%[20]. - The company's total liabilities decreased to RMB 1.62 billion from RMB 1.72 billion, a reduction of 6.1%[20]. - The company's equity attributable to shareholders decreased to RMB 965.43 million from RMB 1.06 billion, a decline of 9.3%[20]. Research and Development - The company's R&D expenses decreased by 27.61% to ¥32,361,278.41, primarily due to reduced investment in R&D projects[10]. - The company incurred research and development expenses of 32,361,278.41 yuan, down from 44,704,949.95 yuan, representing a reduction of approximately 27%[23]. Investment and Financing - Investment income increased significantly to ¥18,799,839.12, a rise of 615.95% compared to the previous year, primarily due to the exclusion of certain pharmaceutical companies from the financial statements[11]. - The company reported investment income of 18,799,839.12 yuan, a significant recovery from a loss of -3,643,763.21 yuan in the previous period[23]. - The company reported a significant increase in short-term borrowings by 36.15%, totaling ¥468,687,948.82[10]. - Short-term borrowings increased to RMB 468.69 million from RMB 344.24 million, an increase of 36.3%[20]. Management and Strategic Initiatives - The company has implemented a "streamlined and efficient" management restructuring, leading to reduced management and sales expenses compared to the previous year[11]. - The company is focusing on market expansion and new product development as part of its strategic initiatives[11]. - The company plans to publicly transfer 90% of its subsidiary Hubei Guangji Pharmaceutical Technology Co., Ltd. at a minimum valuation of RMB 44.7856 million[15]. - Hubei Guanghua Pharmaceutical Co., Ltd. will increase its registered capital by RMB 250 million, introducing at least two strategic investors[16]. - The company completed the transfer of 90% equity in Hubei Guangji Pharmaceutical Technology Co., Ltd. on July 7, 2025[15]. Regulatory and Compliance - The company received a warning and a fine of ¥1.5 million from the China Securities Regulatory Commission for information disclosure violations[14]. Inventory and Credit - The company's inventory stock decreased by 53.40% to ¥9,893,247.00, attributed to the failure of equity incentives to meet performance conditions[10]. - The company reported a significant increase in credit impairment losses, totaling ¥1,760,428.17, up 349.08% year-on-year[11].

Group 1 - Guangji Pharmaceutical experienced a trading halt with a daily turnover rate of 19.88% and a transaction volume of 482 million yuan, showing a price fluctuation of 4.30% [1] - The stock was listed on the Shenzhen Stock Exchange due to a daily decline deviation of -11.36%, with institutional proprietary seats net buying 3.1353 million yuan [2] - The top five trading departments had a total transaction volume of 73.0421 million yuan, with a net selling amount of 2.1292 million yuan [2] Group 2 - The main capital flow showed a net outflow of 9.6793 million yuan, with a significant single order net outflow of 18.9326 million yuan and a large order net inflow of 9.2533 million yuan [2] - Over the past five days, the main capital has seen a net outflow of 52.6351 million yuan [2] - Specific trading details indicate that institutional proprietary seats were involved in both buying and selling, with a total buy amount of 1,006.16 million yuan and a sell amount of 820.34 million yuan [2]

Core Insights - The Hubei state-owned enterprise reform sector experienced a decline of 1.68% on October 24, with Guangji Pharmaceutical leading the drop at -10.05% [1][2] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance Summary - Tianfeng Securities (601162) closed at 5.25, up 0.96%, with a trading volume of 2.7 million shares and a turnover of 1.409 billion yuan [1] - Guangji Pharmaceutical (000952) closed at 6.98, down 10.05%, with a trading volume of 683,800 shares [2] - Wuhan Holdings (600168) closed at 5.57, down 9.58%, with a trading volume of 1.3015 million shares [2] - Hubei Energy (000883) closed at 4.74, down 1.04%, with a trading volume of 482,000 shares and a turnover of 229 million yuan [1][2] Capital Flow Analysis - The Hubei state-owned enterprise reform sector saw a net outflow of 1.154 billion yuan from institutional investors, while retail investors had a net inflow of 794 million yuan [2][3] - Tianfeng Securities had a net inflow of 96.285 million yuan from institutional investors, while retail investors experienced a net outflow of 30.078 million yuan [3] - Hubei Energy had a net inflow of 44.389 million yuan from institutional investors, with retail investors seeing a net outflow of 35.716 million yuan [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.16% on October 24, with Guangji Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Nawei Technology (688690) with a closing price of 29.62, up 8.06% on a trading volume of 127,900 shares and a turnover of 370 million yuan [1] - ST Jingfeng (000908) closed at 7.32, up 5.02% with a trading volume of 228,700 shares and a turnover of 165 million yuan [1] - Major decliners included: - Guangji Pharmaceutical (000952) which fell to 6.98, down 10.05% with a trading volume of 683,800 shares and a turnover of 482 million yuan [2] - Lianhuan Pharmaceutical (600513) closed at 19.22, down 9.04% with a trading volume of 328,300 shares and a turnover of 647 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.529 billion yuan from institutional investors, while retail investors experienced a net inflow of 1.55 billion yuan [2] - The following stocks had significant capital flows: - Beida Pharmaceutical (300558) had a net inflow of 37.25 million yuan from institutional investors [3] - ST Shuangcheng (002693) saw a net inflow of 36.27 million yuan from institutional investors [3]

Core Viewpoint - Guangji Pharmaceutical has experienced a significant surge in stock price, achieving three consecutive daily limit-ups, with a total increase of 33.18% during this period [2] Stock Performance Summary - As of 9:34 AM, the stock price reached 8.55 yuan, with a turnover rate of 8.01% and a trading volume of 27.55 million shares, amounting to a transaction value of 230 million yuan [2] - The stock's limit-up orders totaled 151 million yuan, and the latest total market capitalization of A-shares is 2.965 billion yuan, with a circulating market capitalization of 2.941 billion yuan [2] Trading Data Overview - The stock has been listed on the Dragon and Tiger List due to a cumulative price deviation of 20% over three trading days, with institutional investors net selling 30.09 million yuan while other trading seats collectively net bought 42.08 million yuan [2] - Daily performance data shows fluctuations in trading volume and net capital inflow, with notable increases on October 21 (9.97% increase, 37.44 million yuan net inflow) and October 22 (10.06% increase, 16.51 million yuan net inflow) [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及实际控制人就相关事项进行 了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要补充、更正之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息。 3、近期公司生产经营情况正常，内外部经营环境未发生重大变化。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 湖北广济药业股份有限公司（以下简称"公司"）（证券简称：广济药业，证券代码：000952）股票交易 连续三个交易日（2025年10月20日、2025年10月21日、2025年10月22日）收盘价格涨幅偏离值累计超过 20%。根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 4、公司及控股股东、实际控制人不存在应披露而未披露的重大事项，或处于筹划阶段的重大事项。 5、股票交易异常波动期间，公司控股股东、实际控制人未发生买卖本公司股票的情形。 三季度报告》。 ...

（文章来源：证券日报） 证券日报网讯 10月22日晚间，广济药业发布公告称，公司股票交易连续三个交易日（2025年10月20 日、2025年10月21日、2025年10月22日）收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动的 情况。经核实，公司前期披露的信息不存在需要补充、更正之处；公司未发现近期公共传媒报道了可能 或已经对本公司股票交易价格产生较大影响的未公开重大信息；近期公司生产经营情况正常，内外部经 营环境未发生重大变化。 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-051 4、公司及控股股东、实际控制人不存在应披露而未披露的重大事项，或处 于筹划阶段的重大事项。 湖北广济药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 湖北广济药业股份有限公司（以下简称"公司"）（证券简称：广济药业， 证券代码：000952）股票交易连续三个交易日（2025 年 10 月 20 日、2025 年 10 月 21 日、2025 年 10 月 22 日）收盘价格涨幅偏离值累计超过 20%。根据《深圳 证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及 实际控制人就相关事项进行了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要补充、更正之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司生产经营情况正常，内外部经营环境未发生重大 ...

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]